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Abstract
In the last decade, cancer research has been a highly active and rapidly evolving scientific area. The ultimate goal of all
efforts is a better understanding of the mechanisms that discriminate malignant from normal cell biology in order to allow
the design of molecular targeted treatment strategies. In individual cases of malignant model diseases addicted to a
specific, ideally single oncogene, e.g. Chronic myeloid leukemia (CML), specific tyrosine kinase inhibitors (TKI) have indeed
been able to convert the disease from a ultimately life-threatening into a chronic disease with individual patients staying in
remission even without treatment suggestive of operational cure. These developments have been raising hopes to transfer
this concept to other cancer types. Unfortunately, cancer cells tend to develop both primary and secondary resistance to
targeted drugs in a substantially higher frequency often leading to a failure of treatment clinically. Therefore, a detailed
understanding of how cells can bypass targeted inhibition of signaling cascades crucial for malignant growths is necessary.
Here, we have performed an in vitro experiment that investigates kinetics and mechanisms underlying resistance
development in former drug sensitive cancer cells over time in vitro. We show that the dynamics observed in these
experiments can be described by a simple mathematical model. By comparing these experimental data with the
mathematical model, important parameters such as mutation rates, cellular fitness and the impact of individual drugs on
these processes can be assessed. Excitingly, the experiment and the model suggest two fundamentally different ways of
resistance evolution, i.e. acquisition of mutations and phenotype switching, each subject to different parameters. Most
importantly, this complementary approach allows to assess the risk of resistance development in the different phases of
treatment and thus helps to identify the critical periods where resistance development is most likely to occur.
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Introduction
The variety of approaches in cancer research ranges from
clinical studies, experimental studies in vivo and vitro and genetic
analysis to computational and mathematical models. Due to the
insights from all these domains it was possible to develop specific
targeted therapies for many cancer types and maybe cures for
some are within reach [1]. A very promising example is the
progress in treatment of patients with chronic myeloid leukemia
(CML). CML is caused by a single reciprocal chromosomal
translocation between the long arms of chromosome 9 and 22, the
so called Philadelphia chromosome, in a hematopoietic stem cell
[2]. The resulting BCR-ABL fusion gene encodes for a constitutive
active tyrosine kinase, which is expressed and active in almost all
haematopoietc cells and which leads to accelerated cell cycle
activity [3]. As a result predominantly white blood cells at all stages
of differentiation are significantly increased in peripheral blood
and bone marrow of affected patients. Some years ago the
standard treatment in the chronic phase was interferon-alpha and
after disease progression chemotherapy with or without hemato-
poietic stem cell transplantation, a procedure that is associated
with significant side effects and risks. The treatment algorithms
changed due to the development of tyrosine kinase inhibitors
(TKI) such as Imatinib [4], Nilotinib [5], Dasatinib [6] and
Bosutinib [7]. These molecules bind specifically to the kinase
domain of BCR-ABL and thereby strongly suppress the prolifer-
ation capability of CML cells. Since normal cells are less affected
by this treatment, it allows normal hematopoiesis to be restored
[8]. Long time clinical studies investigating the effect of TKIs show
overwhelming success [4,9,10]. Unfortunately, there are cases in
which patients do not respond to the drug or develop resistance
during the treatment. This raises the question of how BCR-ABL
positive cells bypass inhibition and develop resistance. A large
number of in vivo and in vitro studies were performed, which
identified different mutations causing resistance to TKIs [11,12].
However, the spatial structure and thus the molecular mechanism
of kinase domain binding various between different tyrosine kinase
inhibitors and thus clones resistant to one inhibitor may be
sensitive to an alternative inhibitor. Unfortunately, there are
clones resistant to several inhibitors at the same time. For example
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resistance to all approved TKIs. Agents as Ponatinib have been
particularly designed to bind to such mutated kinase domains of
BCR-ABL and suppress cell proliferation. These are in clinical
trials and showing promising results [13–15]. Also many
mathematical models concentrate on the probabilities and the
dynamics of the development of such cross resistance and how to
reduce the risk of resistance evolving to a minimum using
combination therapies of different drugs [16–18]. We will not
focus on this aspect in the following, but address the dynamics of
resistance development instead.
Here, we discuss an experimental setup that induces resistance
to Imatinib in initially sensitive BCR-ABL positive Ba/F3-p210
cells. In the following our aim is not to assess the probability of the
occurrence of a specific resistance-conferring mutations nor to
identify novel mutations, but to focus on the clonal dynamics that
occurs during such an experimental setup. Instead, we show that
not only mutations, but also intracellular processes that do not lead
to any mutations can lead to the development of resistance. We
investigate the average fitness of cancer cells exposed to a drug
concentration that increases over time in this in vitro experiment.
Basic features of this dynamic can be explained by a mathematical
model, assuming a fitness of cancer cells that decreases with time
as the drug concentration increases. By comparing the experi-
mental data with simulation and analytical results we were able to
assess individual parameters in this model and gain insights into
the general cancer cell population dynamics under such
environmental situations.
Materials and Methods
Materials
Imatinib was purchased from Toronto Research Chemicals Inc,
Ontario, Canada. Stock solutions of IM (10 mg/mL; in DMSO/
H2O (1:1)) was stored at 200C. Murine BCR-ABL transduced pro-
B cell line Ba/F3-p210 was obtained from N.P. Shah and C.L.
Sawyers (UCLA, USA). Cells were cultured under standard
conditions as previously described [19].
Cell culture approach for induction of Imatinib resistance
In this experiment, Ba/F3-p210 cells carrying the BCR-ABL
kinase were used as a model for resistance development to IM
treatment, following a well established protocol [20]. Flow
cytometry based cell sorting using a FACSAria (BD Biosciences)
was employed to produce 10 clones of BaF/3-p210 cells. These
clones were expanded to cultures of 2|105 cells each. These
cultures were exposed to Imatinib in a concentration increasing
over time, starting with 0:1mM. Cell viability was measured by the
Trypan blue exclusion method [21]. The Imatinib concentration
was periodically increased by 0:1mM only if cell viability was
above 70%, the concentration stays unchanged if the cell viability
is between 30% and 70% and withdrawn in case of cell viability
less than 30%. Thus the time the Imatinib concentration was
increased differed for different clone lines, but the concentration
was always increased within 12 days. Parallel, a control with
untreated clones was performed. At the end of the experiment all
Imatinib treated lineages were resistant to the drug, confirmed by
a cytotoxicity MTT-assay.
MTT assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyÆltetrazoliumbro-
mide (MTT) assay was performed as previously described [22].
In brief, BAF/3-p210 cells were plated into 96-well flat-bottomed
microtiter plates (Becton Dickinson, Heidelberg, Germany) at
1:5|104 cells/well in 150mM of their respective media. Cells
were preincubated for 24 hours before increasing concentrations
of Imatinib (0–10mM) were added. All analyses were performed in
triplicates. After 48 hours, the viable cells in each well were
assayed. The dose-response effect for Imatinib at the point of
inhibitory concentration (IC50) was analyzed by the median-effect
method with CalcuSyn Software (Biosoft, Cambridge, United
Kingdom) [23].
Mutagenesis screen and real time PCR for BCR-ABL
transcript
To identify possible BCR-ABL kinase domain mutations as
mechanism of Imatinib resistance, the coding cDNA of the kinase
domain was sequenced. For all RT-PCR reactions, total RNA was
isolated using TRIzol (Invitrogen). cDNA was prepared by reverse
transcription of 250 ng RNA with oligo(dT)15 and Superscript II
reverse transcriptase (Invitrogen) and amplified using REDTaq
ReadyMix PCR Reaction Mix (Sigma-Aldrich). BCR-ABL allele
was amplified by nested PCR using BCR forward primer B2A(59-
TTCAGAAGCTTCTCCCTGACAT-39) and ABL reverse prim-
er 4065 (59-CCTTCTCTAGCAGCTCATACACCTG-39). Nest-
ed PCR reactions were performed using BCR F4 forward (59-
ACAGCATTCCGCTGACCATCAATA-39) and reverse U396
(59-GCCATAGGTAGCAATTTCCC). PCR products containing
the kinase domain were sequenced with both forward primer
3306F (59-TGGTTCATCATCATTCAACGG-39) and reverse
primer 4000R (59-GGACATGCCATAGGTAGCA-39). Real
time PCR for BCR-ABL was performed as previously described
[24,25]. Amplification of ABL was used as a internal housekeeping
gene.
Quantification of MDR-1 on resistant clones
For the relative quantification of MDR-1 we used a flow
cytometry-based assay. Cells were fixed in 2% formaldehyde for
10 minutes at 370C, chilled on ice for 1 minute, and then
permeabilized with ice-cold 90% methanol for 30 minutes on ice.
From each sample, 2|105 cells were washed with 2 mL
incubation buffer (PBS/0.5% bovine serum albumin), centrifuged
at 50 g for 5 minutes, and resuspended in 100mL of incubation
buffer with 2:0mL of a MDR-1 specific antibody (abcam,
Cambridge, UK). After 45 minutes of incubation at RT, cells
were washed twice, resuspended in 100mL incubation buffer with
0:5mL of the secondary antibody (anti-rabbit IgG FITC-
conjugate; Jackson ImmunoResearch Europe, Newmarket, United
Kingdom), and incubated at RT for 30 minutes in the dark. After
washing two times with washing buffer cells were analysed using
flow cytometry.
Individual based model
We compare the dynamics in the mathematical model to the
experiment based on the fitness of cells. We assume that the
average fitness of the experimental cell population is the ratio
between the number of vital cells and the total number of cells.
Mathematically we model the cell population dynamics observed
in the experiment by an individual based stochastic approach,
applying a standard two type Moran process [26,27]. We assume a
population of N~2|105 cells consisting of two subpopulations,
wild type leukemic cancer cells sensitive to Imatinib and Imatinib
resistant cancer cells. Initially, only wild type cancer cells are
present, but transformations from wild types into the resistant type
are possible. In each time step, one cell is chosen to reproduce and
one cell is chosen to die, thus the total number of cells stays
constant and the subpopulation sizes can change at most by 1 cell
Resistance Development to Imatinib
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to reproduce, an Imatinib resistant cancer cell is produced with a
transformation probability u. To avoid complications, we assume
that resistant types cannot switch back to nonresistant types. This
would not change the basic results, however. The two types differ
in their fitness fw (for the wild type) and fr (for the resistant type)
We assume a time dependent wild type fitness function, due to the
increasing concentration of Imatinib in the experiment. We set the
fitness of untreated wild types fw to one and assume that it
decreases linearly with increasing Imatinib concentration,
fw t ðÞ ~
1{
t
t  0ƒtƒt 
0 otherwise:
8
<
:
ð1Þ
The parameter t  determines the impact of Imatinib on wild
type cells. Choosing other decreasing functions, e.g. an exponen-
tially decreasing function, does not change the results qualitatively.
For the Imatinib resistant subpopulation we assume constant
fitness, fr~const. For frvfw, resistant cells proliferate slower than
wild type cells, for frwfw they proliferate faster than wild type
cells. The experimental data suggest 0vfrv1 and thus initially
resistant types would initially be out-competed by wild type cells,
see below. Due to the decreasing fitness of wild type cells, we can
go from one domain to the other in time. We assume that cell
reproduction occurs proportional to fitness and simultaneously a
random cell is chosen to die. Thus, the probability of increasing or
decreasing the number of resistant cancer cells i at time t is
notated by Tz
i or T{
i respectively,
Tz
i ~
ifr
ifrz N{i ðÞ fw
zu
N{i ðÞ fw
ifrz N{i ðÞ fw
  
N{i
N
ð2aÞ
T{
i ~ 1{u ðÞ
N{i ðÞ fw
ifrz N{i ðÞ fw
  
i
N
: ð2bÞ
The number of resistant cells stays unchanged with probability
T0
i ~1{Tz
i {T{
i . One generation consists of N reproduction
and death events, such that each cell reproduced on average once.
Analytical approximation for large population size
If the population size N is large, we can describe the averages of
our individual based model by a deterministic approach. In this
case, we consider the frequency (relative population size) of the
two cell types, wild type leukemic cells with frequency
wt ðÞ ~(N{i)=N and Imatinib resistant cell types with frequency
rt ðÞ ~i=N. We use the same fitness functions as above and also
assume transformations from the wild type to the resistant type.
The average fitness of the system, which has been measured in the
experiment, is given by W t ðÞ ~wt ðÞ fw t ðÞ zrt ðÞ fr. The change in
wild type and resistant type frequencies for large populations are
given by a replicator mutator equation [27,28]
_ w w~wf w{W ðÞ {ufww ð3aÞ
_ r r~rf r{W ðÞ zufww, ð3bÞ
where the dot represents a derivative with respect to time t. With
the functions from above, these differential equations take the form
_ w w~
w 1{w ðÞ 1{fr{
t
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{u 1{
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t 
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These are time dependent nonlinear differential equations of the
Bernoulli type, for which a general solution scheme exist [29].
Thus the system of differential equations can be reduced to
integrals, which in this situation are solvable. Due to
wt ðÞ zrt ðÞ ~1, we only have to solve one of the equations. The
general solution for w(t) with respect to the initial condition
w 0 ðÞ ~1 for tƒt  reads
w(t)~
1{u
1{ue
h2
t {h2
0z
ﬃﬃﬃﬃﬃﬃﬃ
pt 
2
r
ufr ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1{u
p eh2
t Erf ht ðÞ {Erf h0 ðÞ ½ 
, ð5Þ
where ht~
1{u ðÞ
t
ﬃﬃﬃﬃ
t  p z
ﬃﬃﬃﬃ
t  p
fr{1zu ðÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
21 {u ðÞ
p and
Figure 1. Individual based stochastic simulation as two type
Moran process. We assume two possible cell types, wild type
leukemic cancer cells sensitive to Imatinib (yellow) and resistant cancer
cells (blue). In total, &2|105 cells were included in the experiment and
simulations. At time t there are i resistant cells and N{i wild type cells.
During the next time step tz1 three cases are possible: (i) the number
of resistant cells increases by one with probability Tz
i , (ii) stays the
same with probability T0
i ~1{Tz
i {T{
i (iii) or decreases by one with
probability T{
i , (see equation (2a) and (2b)).
doi:10.1371/journal.pone.0028955.g001
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is the error function. For t%1, this can
be approximated by
w(t)&1{utzu
1z(1zu{fr)t 
2t  t2zo½t3 :
For t§t , the number of resistant cells grows logistically and
consequently, the number of wild type cells decreases logistically
wt ðÞ ~
1
1z
1{wt   ðÞ
wt   ðÞ
e{fr(t{t )
: ð6Þ
The average fitness of the total population becomes
W t ðÞ ~fr 1{wt ðÞ ðÞ z 1{
t
t 
  
wt ðÞ : ð7Þ
For small t, when w(t) is approximately constant, the average
fitness decreases approximately linearly determined by t .
Results
Development of Imatinib resistance in cell culture
Using an in vitro approach to induce Imatinib resistance under
increasing selection pressure, we detected resistance in 10 out of 10
BAF/3-p210 clones. As depicted in Fig. 2A the development of
Imatinib resistance was associated with a significant decrease in
the population doupling compared to control cells. The observed
development of Imatinib resistance resulted in an significant
increase of the IC50 for Imatinib in all, but one clones (Fig. 2 B).
For four resistant clones, it was possible to identify previously
known resistance mutations in the BCR-ABL kinase domain.
These were the D276G (prevents Imatinib from binding to BCR/
ABL), E355G (blocks the TK catalytic centre) and L284M
(inactivates the kinase) mutations (Fig. 2 C). No mutations of the
kinase domain were found in the other clones, nevertheless they
also developed resistance to Imatinib. In order to explore if the
resistance in the non-mutated clones is based on an increased
BCR-ABL expression we employed real time PCR for quantifi-
cation of the BCR-ABL transcript. As depicted in Fig. 2 D we
could only identify an up-regulation of BCR-ABL expression in
one single clone. Furthermore, there was no increased expression
of the ABC-transporter MDR-1 on resistance cell clones (Fig. 2 E).
Based on these findings, we concluded that mechanisms other than
kinase domain mutations, BCR-ABL over expression or MDR-1
up-regulation have lead to resistance in these cases.
Fitting the mathematical model to the experimental data
We now focus on the dynamics of the cell population. Initially,
the average fitness of the total population decreases as the Imatinib
concentration increased. At day 24 of the experiment, a global
fitnessminimumof W~0:706 (experimental data) is obtained (Fig. 3
A).Subsequently, the averagepopulation fitness increased,although
the environmental conditions become more challenging due to the
ongoing increase of the Imatinib concentration. From day 48 until
the end of the experiment the average fitness of the population was
saturated and fluctuated around W~0:83+0:03. Our mathemat-
ical model offers a simple explanation for this result: In the
beginning, only wild type cancer cells with decreasing fitness are
present (Fig. 3 B). During the experiment, the frequency of resistant
cell types increased and once they represent the bulk of the
population, the average population fitness becomes independent of
a further increase of Imatinib concentration. Consequently, the
average fitness becomes constant. While it is challenging to analyze
the underlying mechanisms of resistance evolution, we were able to
adress the parameter ranges in the experiment based on our model.
First, we fixed time scales to make experimental and simulation
results comparable. In the control experiment, untreated wild type
cancer cells were grown in a regular growth medium and the
population doubling times were recorded. We compare these
doubling times to one generation in our simulation, which we
define here as N reproduction events in a population of size N.
We found on average a doubling rate of 0:48+0:01 per day in the
experiment, thus one generation in silico approximately relates to
two days in vitro.
The initial fitness decrease was determined by the fitness
decrease of wild type cells only and thus allowed us to fix the
parameter t  by linear regression of the average population fitness
on day 0, 12 and 24, leading to t ~82+4days. Thus, assuming a
linear decrease of fitness according to equation (1) the wild type
fitness would reach zero on day 82 of the experiment (dashed black
line in Fig. 3 A). Such an assumption of zero fitness is probably
biologically not meaningful. However, our simulation results
remain unchanged if we assume that the lowest possible fitness
value of wild type cells is 0.5. This would be reached at day 40 of
the experiment, where the resistant cell type already took over the
population as shown in Fig. 3 B.
In our model the average fitness of the total population becomes
constant at high Imatinib concentrations, because the resistant cell
types take over the cell cultures. This fixed the average fitness of
the resistant cell types to fr~0:83+0:02 (averaged from day 48
on).
The only remaining free parameter is the switching probability
u, which is more difficult to assess. To determine u, we fixed t  and
fr as discussed above and performed individual based stochastic
simulations, which suggests that a switching probability between
10{6ƒuƒ10{4 is compatible with the experiment. Smaller
values of u would cause a later increase in frequency of resistant
cell types, but as soon as a certain fraction of resistant cells are
present they fixate faster. For higher values of u the minimum of
the average fitness W would be reached earlier. We also performed
a non linear fit of equation (7) with the full solution for w(t),
equation (5). The best fit yields a value of u~10{4. Note that
u~10{4 is too high to call this parameter a mutation rate.
However, in the experiment only in 4 out of 10 samples mutations
known for causing resistance to Imatinib were found.
To take these two different experimental outcomes into account,
we performed the procedure described above independently for
samples with and without mutations. The result is shown in Fig. 4.
In samples where mutations were detected, we observe
u~1|10{6, fr~0:88. In the case of no detected mutations, we
found u~6|10{4 and fr~0:82. Thus, the transformation
probability differs by magnitudes and samples with mutations
seemed finally fitter than samples without mutations. This leads to
the possibility that two mechanism may cause resistance, mutation
and a sort of phenotype switching. We extended our model to
incooperate these two distinct effects, as shown in Fig. 5. With this
extension, wild type cells switch into mutated cells (M) with
probability uM~1|10{6 and fitness fM~0:88. Alternatively,
they switch into transformed types (T) with probability
uT~6|10{4 and fitness fT~0:82. Additionally, transformed
types (T) can mutate with probability uM into mutated types (M).
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28955Figure 2. Experimental results. A) Average population doubling time observed for BAF/3-210 cells with (white triangles) and without (black dots)
long-term Imatinib treatment. The number of population doubling for control cells was significantly higher compared to IM-treated cells. B)
Measurment of IC50 for Imatinib in control and resistant clones. The long-term presence of Imatinib increase the IC50 in all resistant cell clones. In
particular, cell clones which were growing at 1 M Imatinib showed a marked increase of the IC50 value. The cell viability was determined using MTT
assay and IC50 was calculated CalcuSyn software. C) Schematic representation of in vitro detected BCR-ABL mutations. D) Quantification of BCR-ABL
transcript by reat-time PCR in resistant clones without BCR-ABL mutations. Only one clone (K10) exhibited an increased expression of BCR-ABL. E)
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wild type cells are present in the simulation. Due to the higher
switching probability transformed types take over almost the whole
population, but due to their fitness advantage and the directed
mutations in the long run the mutant types fixate. However the
experiment was stopped after 120 days. In the experiment we
found mutant types in 4 out of 10 samples. At this time we observe
frequencies of 0.43 for mutated types and 0.57 for transformed
types in the simulation, compatible with the experiment. Also in
the simulation, the average fitness of the population goes through a
minimum, but the fitness still increases after 120 days, because the
mutant type does not reach fixation yet.
Discussion
Resistance to TKI is a frequent clinical problem in treatment of
CML patients. The appearance of resistant cell clones undermines
our abillity to control the malignant BCR-ABL positive cell clone
and thereby prevent the successful treatment of CML patients.
The mechanisms of TKI resistance are either BCR-ABL
dependent or BCR-ABL independent [30]. Mutations in the
BCR-ABL kinase domain represent the most frequent BCR-ABL
dependent mechanisms. On the other hand, overexpression of
BCR-ABL and overexpression of drug transporters are known
kinase independent mechanisms of TKI resistance. The rise of
drug resistance is a evolutionary process characterized by a
competition between sensitive and resistant cells but not an active
process of resistance induction by the drug [31].
Using a combination of a clonal in vitro approach for induction
of Imatinib resistance and mathematical modeling, we were able
to explain the dynamics of the average fitness of Imatinib treated
cancer cell populations in vitro in a simple model assuming that:
N The population consists of only three subpopulation, the wild
type cancer cells (the only cell type present at the beginning of
the experiment) and resistant cell types (mutated and
transformed cells).
N The fitness of wild type cells decreases with increasing drug
concentration over time. The fitness of resistant types is lower
than the wild type fitness, but both are constant.
N We introduced directed transformation. Wild types transform
into resistant types, the reversal is neglected.
With these assumptions, we provided a method to fix the model
parameters and thus get some insights into the mechanism that
cause the dynamics. Comparing the analytical solution with
experimental results enabled us to fix important parameter of the
system. Accordingly, it is possible to derive a range for the
transformation probability u, which is 10{6ƒuƒ10{4 for this
experimental setup. This is high compared to values normally
assumed for mutations, which seems to be about 10{8 for normal
cells. But the mutation rate of malignant cells has been reported to
be at least 10{1 to 10{2 higher [32,33]. If we perform our analysis
separately for the samples with and without mutations, we find
different parameter values. For the mutated cell lines, we found
uM~1|10{6, which is in the expected range for mutation rates
of such malignant cells. But for samples without mutations, we find
uT~6|10{4. This supports the idea that not only mutations are
responsible for drug resistance evolution in this case, but that also
other mechanisms are likely to be involved [34]. Noteworthy, we
could not detect BCR-ABL- or MDR-1 overexpression as the
reason for resistance. However, there is some evidence that an
activation of additional pathways, like the phosphatidylinositol-3-
kinase (PI3K)-AKT pathway [20] or Src family kinase [35,36], can
compensate for the BCR-ABL inhibition and can promote the
proliferation of these cells in the presence of Imatinib. From our
mathematical model and our experimental results, one can
conclude that particularly the time frame between day 24 and
day 48 is crucial for development of resistance. It can be
speculated that starting with day 24, the cells launch out to adapt
their metabolism to the increasing pressure of raising Imatinib
concentrations. This kind of adaptions are normaly accompanied
by an activation of novel signaling pathways and can drive the
cellular metabolism of resistant cells to an increased glycolytic
activity and phospholipid turnover [37,38]. In this context, our
model represents a basis to determine the critical time point and
Imatinib concentration for further studies to detect novel BCR-
ABL independent resistance mechanisms. This should be done by
a comprehensive and integrative genome-, transcriptome-, pro-
teome- and metabolome analysis and may lead to additional
insights into activated pathways of resistant CML cells. Recent in
vitro and in silico studies have revealed that a combination of
drugs with different mode of actions can prevent treatment failures
due to drug resistance [16–18,39]. However, the appropriate
targets are not defined and must be elucidate in further studies.
Quantification of MDR-1 expresion by flow cytometry in resistant clones without BCR-ABL mutations. Imatinib resistance was not associated with an
increased expression of MDR-1.
doi:10.1371/journal.pone.0028955.g002
Figure 3. Dynamics of resistance development in the experi-
ment and the mathematical model. A) Average fitness of the total
population due to experiments (black dots), stochastic simulations
(green dots) and analytical results (black line, due to equation (7)). The
parameters of simulation and calculation were chosen to N~2|105,
u~1|10{4, t ~80 days and b~0:83. The dashed red line shows the
linear decrease of the wild type fitness, the slope is determined by the
critical time t . B) The average frequency of wild type cells due to
simulation (yellow dots) and calculation (black line), as well as the
frequency of resistant cancer cells (blue dots) over time. We always start
with wild types only, but since the system selects for resistant cells, they
fixate in the long run. This is why the average fitness of the total
population exhibits a minimum. At the start of the experiments, the
fitness of wild types decreases, but after some time resistant cells take
over and the fitness increases until it saturates.
doi:10.1371/journal.pone.0028955.g003
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resistance is associated with reduced fitness of resistant cells in vitro.
Translating this into fitness in vivo can be challenging, due to
additional aspects as the hierarchical structure of hematopoiesis
[40–42], failed targeting of cancer stem cells, for example due to
quiescent cells, [43,44] and possible aging effects [45]. Furthermore
very small differences in vitro can cause important measurable
differences in vivo, but also in this case mathematical approaches
can be helpful [46]. Notably, the fitness of clones harboring a BCR-
ABL mutation was higher compared to the unmutated clones. This
might be due to the proposed switch on alternative or additional
programs in unmutated clones which may be costly in terms of
proliferation, but enable the cell to function independent of the
BCR-ABL kinase. Based on recent studies, it can be speculated that
in mutated clones the mutations are preexisting and the cells do not
need to adapt their metabolism to reach resistance [47]. In this case
the reduced fitness reflect the differences between mutant and wild-
type BCR-ABL. Recent studies have revealed that certain mutated
BCR-ABL kinases are accompanied by reduced oncogenic activity
[48,49]. These findings are supported by clinical studies. Hanfstein
et al. have shown a deselection of mutant BCR-ABL positive clones
after cessation of tyrosine kinase inhibitor [50], as also suggested by
mathematical models [8,51]. Fitness costs are commonly associated
with drug resistance. Particularly, resistance against antibiotics is
frequently observed in vitro and in vivo and is associated with
reduced fitnessof resistant clones [52,53].In comparison to that,the
existence of a fitness cost in resistance to cancer drugs has not been
analysed in detail yet. Therefore, our data represent an appropriate
model to further investigate in this cellular behavioral pattern.
Acknowledgments
We thank Silke Zeschke for her technical assistance in this work. Further
we thank David Dingli and Tom Lenaerts for helpful discussions on this
manuscript.
Author Contributions
Conceived and designed the experiments: SB THB. Performed the
experiments: DL SB. Analyzed the data: BW DL AT SB. Wrote the paper:
BW THB AT SB. Conceived and designed the mathematical model: BW AT.
Figure 4. Average fitness observed for samples A) with and B) without detected mutations. The black dots are due to data and the green
dots due to simulations. The evaluated parameters differ (see the inset of the plots), the fitness of the mutated cells is on average higher but their
transformation rate is much smaller.
doi:10.1371/journal.pone.0028955.g004
Figure 5. Stochastic simulations with three subpopulations. A)
Transitions between the three types considered, wild types (W),
resistant types without observed mutations (T) and resistant types
with observed mutations (M). The switching probabilities are according
to the arrows. B) Average fitness of the system described in a) due to
simulations (green dots) and experimental data (black dots, as
described in figure 3). The parameters are those observed in figure 4.
C) Average frequency of the three types. Initially, only wild types
(yellow line) are present, at day 37 of the experiment resistant types
without observed mutations (T, dashed blue line) reach almost fixation,
but in the long run mutated types (M, blue dots) take over due to their
fitness advantage. At day 120 of the experiment we have 0.57 T types
and 0.43 M types (6 T and 4 M types were observed in the experiment
at day 120).
doi:10.1371/journal.pone.0028955.g005
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